Testing Services Market Outlook, 2025-2035
Testing Services Market Outlook, 2025-2035 - Dominated by Charles River Laboratories Int'l, Eurofins Scientific, SGS, WuXi AppTec, and Pace Analytical Services
The "Global Preclinical Medical Device Testing Services Market by Service, By Testing Type, by End-User, and By Region" report has been added to ResearchAndMarkets.com's offering. This comprehensive research report focuses on the global and regional market size and forecasts from 2024 to 2035.
The global preclinical medical device testing services market is estimated to be USD 3.91 billion in 2024 and is expected to reach USD 10.34 billion by 2035, with a CAGR of 9.24% during the forecast period 2025-2035. Regulations and compliance requirements are becoming more and more stringent. The market will develop due to the emergence of advanced testing technologies, the growing trend of outsourcing in R&D, and the increased focus on patient safety and product quality.
In response to increasing patient safety concerns and a heightened emphasis on product quality, manufacturers in the medical device industry are prioritizing high-quality, accurate preclinical testing. There is a growing demand for testing services that minimize risks and enhance device reliability, as these measures are essential to prevent device recalls and improve patient outcomes. A notable development in this arena occurred in November 2023 when Crown Bioscience, in collaboration with JSR Life Sciences, announced the launch of OrganoidXplore. This innovative service offering provides robust, reproducible, and clinically relevant outputs, significantly accelerating preclinical oncology drug discovery. By reshaping the landscape of cancer treatment development, OrganoidXplore exemplifies the commitment to advancing product quality and enhancing patient safety in the medical device sector.
North America is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high R&D investment in medical technology, and the presence of leading medical device companies and regulatory agencies such as the FDA, which mandates stringent testing standards.
Additionally, Asia Pacific is predicted to grow at the fastest CAGR during the forecast period owing to the expanding medical device market, rising healthcare expenditure, increasing outsourcing of testing services, and supportive government initiatives to enhance healthcare quality and regulatory compliance. For instance, Glucotrack, Inc. reported in October 2023 that it has started preclinical animal research for an implanted continuous glucose monitor (CGM).
